MoonLake Immunotherapeutics (MLTX), a clinical-stage biotechnology company, is gearing up for highly anticipated near-term data readouts tied to its lead drug candidate, Sonelokimab, a potential treatment for autoimmune conditions.
Sonelokimab works by targeting and neutralizing specific proteins in the body called interleukins, particularly IL-17A, IL-17F, and IL-17A/F. These interleukins are involved in causing inflammation in various autoimmune conditions. By blocking these proteins, Sonelokimab may help reduce inflammation and improve symptoms in patients with psoriasis, psoriatic arthritis, and hidradenitis suppurativa. (Source: ClinicalTrials.eu)
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.